NCT01087021 - Effect of Cabazitaxel on the QTc Interval in Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

November 30, 2011

Conditions

Neoplasms, Malignant

Interventions

DRUG

Cabazitaxel (XRP6258)

"Pharmaceutical form:solution for infusion~Route of administration: intravenous"

Trial Locations (15)

Sanofi-Aventis Investigational Site Number 056002, Brussels

Sanofi-Aventis Investigational Site Number 208001, København Ø

Sanofi-Aventis Investigational Site Number 208002, Herlev

Sanofi-Aventis Investigational Site Number 056001, Ghent

Sanofi-Aventis Investigational Site Number 840009, Bethlehem

Sanofi-Aventis Investigational Site Number 840010, Paducah

Sanofi-Aventis Investigational Site Number 840005, Decatur

Sanofi-Aventis Investigational Site Number 840007, Kansas City

Sanofi-Aventis Investigational Site Number 840008, Wichita

Sanofi-Aventis Investigational Site Number 840003, Salt Lake City

Sanofi-Aventis Investigational Site Number 840006, San Diego

Sanofi-Aventis Investigational Site Number 840002, San Francisco

Sanofi-Aventis Investigational Site Number 528001, Maastricht

Sanofi-Aventis Investigational Site Number 752002, Lund

Sanofi-Aventis Investigational Site Number 752001, Uppsala